Pestalozzi advises H.C. Wainwright & Co in USD 20m underwritten offering and concurrent private placement in ObsEva SA
ObsEva SA, a Swiss clinical-stage biopharma company listed at SIX Swiss Exchange and Nasdaq, announced today the pricing of an underwritten equity offering and concurrent private placement. H.C. Wainwright & Co. is acting as sole book-running manager for the underwritten offering, consisting of 6'448'240 units of one common share (or pre-funded warrant) and one 15-month purchase warrant each, and as exclusive placement agent for the private placement, consisting of 516'325 such units. The aggregate gross proceeds from the underwritten offering and the private placement amount to approx. USD 20m and potential gross proceeds from the purchase warrants amount to USD 23.9m.
Pestalozzi advised H.C. Wainwright & Co. as to all matters of Swiss law and rules of the SIX Swiss Exchange.